Tous Actualités
Suivre
Abonner LAB International Inc

LAB International Inc

LAB International Shares Trading on the Frankfurt Stock Exchange

Laval, Quebec (ots/PRNewswire)

LAB International Inc. (TSX: LAB,
Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development
company focused on the inhalation market, today announced that its
shares are available for trading on the Regulated Unofficial Market
(Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the
Deutsche Borse AG electronic trading system. The inclusion of LAB's
securities in the Regulated Unofficial Market is pursuant to an
application made by a member-trading firm of the Frankfurt Stock
Exchange to assume specialist responsibility for the stock and annual
exchange fees.
"We are pleased by the volume generated so far on the Frankfurt
Stock Exchange and XETRA(R), which confirms the demand for our shares
from European investors. This enhanced exposure and liquidity will
benefit all LAB shareholders," said Dr. Halvor Jaeger, CEO of LAB.
"With operations in Hungary and Finland, and a European partner for
our lead product Fentanyl Taifun(R), we have a significant presence
in the European market."
As a company already listed on a recognised Stock Exchange (TSX),
there are no obligations or additional disclosure requirements to
either the Frankfurt Stock Exchange or German financial supervisory
authority resulting from the inclusion on the Freiverkehr.
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated
drug development company. LAB Pharma is focused on the growing
multi-billion dollar inhalation market. Its lead product, for the
treatment of breakthrough cancer pain, is a fast-acting Fentanyl
formulation delivered using the Company's approved Taifun(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for
asthma, COPD, and growth hormone deficiencies. LAB Research is a
profitable and growing contract research services division supporting
more than 300 clients from state-of-the-art facilities in Canada, the
US, and Europe.
LAB's common shares trade on The Toronto Stock Exchange ("TSX")
under the symbol "LAB" with 38.8 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of LAB International
Inc. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly.
www.labinc.ca

Contact:

For further information: visit LAB's website at www.labinc.ca, or
contact: Luc Mainville, Executive Vice-President, Tel:
+1-(450)-973-2240 ext. 1206, Fax: +1-(450)-973-2259,
mainvillel@labinc.ca; Frederic Dumais, Director, Communication and
Investor Relations, Tel: +1-(450)-973-2240 ext. 1207, Fax:
+1-(450)-973-2259, dumaisf@labinc.ca; James Smith, Investor
Relations, Tel: +1-(416)-815-0700 ext. 229, Fax: +1-(416)-815-0080,
jsmith@equicomgroup.com

Plus de actualités: LAB International Inc
Plus de actualités: LAB International Inc
  • 06.12.2004 – 18:16

    LAB International to Initiate Phase II Trial for GHRH

    Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...